Gina Mauro

The use of artificial intelligence led to a higher rate of breast cancer detection as an improvement for mammography screening compared with standard detection methods.

The approved combination of enfortumab vedotin and pembrolizumab provides an alternative to chemotherapy for patients in China.

Arlo-cel yields responses among patient subgroups, including those with triple class–refractory disease and extramedullary disease.

The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.

Active monitoring had similar rates of invasive cancer in the ipsilateral breast as guideline concordant care for the low-risk DCIS population.

Autologous transplant did not confer significantly improved overall survival regardless of induction intensity in a phase 3 trial.

For patients with relapsed/refractory diffuse large b-cell lymphoma, meaningful efficacy outcomes were shown with FS118.

Responses with epcoritamab were comparable across the expansion and optimization cohorts in the EPCORE CLL-1 trial.

The incorporation of palliative care specific to mental health services and therapy remains underutilized in the care of patients with pancreatic cancer.

The FDA has approved revumenib (Revuforj) for the treatment of patients with relapsed/refractory acute leukemia with a KMT2A translocation in adult and pediatric patients 1 year and older.

James R. Berenson, MD, discusses serum BCMA and markers for predicting outcomes and monitoring disease in patients with multiple myeloma.

Ginger J. Gardner, MD, FACOG, walked through the strides of gynecologic cancer research and emphasized the efforts that still need to be accomplished.

Concurrent chemoradiation yielded similar contralateral breast recurrence outcomes vs a sequential approach in early-stage breast cancer.

Experimental regimens did not cross the threshold to show superiority vs standard cisplatin plus 70 Gy radiation in those with HPV-associated oropharynx cancer.

The FDA granted traditional approval to selpercatinib for patients with advanced or metastatic medullary thyroid cancer with a RET mutation.

Pluta Cancer Center clinicians discussed how to improve sexual health outcomes for patients diagnosed with gynecological cancer.

The addition of pembrolizumab to chemotherapy with or without radiation did not improve DFS across the intent-to-treat population of KEYNOTE-B21.

Updated findings from the AEGEAN trial support perioperative durvalumab as a new therapy option for those with resectable non–small cell lung cancer.

The addition of neoadjuvant S-1 also reduced the risk of death compared with adjuvant therapy alone in the phase 3 PRODIGY trial.

Targeting multiple survival pathways simultaneously with ViPOR may be effective in specific molecular subtypes of relapsed/refractory DLBCL.

Adding metastasis-free directed radiation to chemotherapy more than tripled progression-free survival vs chemotherapy alone in the EXTEND trial.

Cyclophosphamide-based prophylaxis for GVHD showed similar outcomes across racial subgroups regardless of matched or mismatched unrelated donors.

Frontline zolbetuximab plus chemotherapy is one step closer to approval by the European Commission for select patients with advanced gastric/GEJ cancer.

After allogeneic hematopoietic cell transplantation, pregnancies could be carried out and were successful.

SLS009 is a highly selective CDK9 inhibitor that is being studied in an ongoing phase 1/2 trial for patients with hematologic malignancies.

“This is currently the largest pooled safety dataset for a HIF-2α inhibitor we need to be familiar with,” lead study author Toni K. Choueiri, MD.

Investigators evaluated the impact of low-molecular weight heparin after the first 60 days of treatment as well as treatment overall.

Investigators will assess the clinical activity, safety, and pharmacokinetics of GTB-3650 among those with CD33-expressing cancers in a phase 1 trial.

Frontline acalabrutinib plus bendamustine/rituximab may become a new standard therapy in MCL, according to Michael Wang, MD.